Apitegromab Explored as Adjunctive Therapy for Overweight and Obesity

Globally, obesity and overweight conditions pose significant health risks, often managed with lifestyle interventions and medications like GLP-1 receptor agonists (e.g., tirzepatide). However, current therapeutic strategies may not achieve optimal weight loss for all patients, highlighting a continuous need for innovative treatment options. This Phase 2 study investigates the potential of apitegromab to enhance weight loss outcomes when combined with existing GLP-1 receptor agonist therapy in adults without diabetes.

The provided research record is a study protocol description from ClinicalTrials.gov and, as such, does not contain specific efficacy or safety results from the trial. The study, NCT06445075, is listed as COMPLETED, indicating that participant interventions have concluded, but the data analysis and publication of detailed findings are still pending. Therefore, quantitative data regarding apitegromab's impact on weight loss, changes in body composition, or specific adverse event rates compared to placebo in combination with tirzepatide cannot be reported at this time. > The primary objective of this Phase 2 trial was to evaluate the safety, efficacy, and pharmacokinetics of apitegromab as an adjunctive therapy to tirzepatide for overweight and obesity. Future publications from Scholar Rock, Inc. are expected to detail the specific weight loss percentages, adverse event rates, and pharmacokinetic profiles observed in the apitegromab group versus the placebo group.